JP2004526154A - 細胞ベースの検出および病態の判別 - Google Patents
細胞ベースの検出および病態の判別 Download PDFInfo
- Publication number
- JP2004526154A JP2004526154A JP2002572414A JP2002572414A JP2004526154A JP 2004526154 A JP2004526154 A JP 2004526154A JP 2002572414 A JP2002572414 A JP 2002572414A JP 2002572414 A JP2002572414 A JP 2002572414A JP 2004526154 A JP2004526154 A JP 2004526154A
- Authority
- JP
- Japan
- Prior art keywords
- panel
- probes
- cancer
- probe
- marker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 143
- 201000010099 disease Diseases 0.000 title claims abstract description 139
- 238000001514 detection method Methods 0.000 title claims description 117
- 238000000034 method Methods 0.000 claims abstract description 206
- 230000035945 sensitivity Effects 0.000 claims abstract description 62
- 230000002159 abnormal effect Effects 0.000 claims abstract description 11
- 239000000523 sample Substances 0.000 claims description 515
- 210000004027 cell Anatomy 0.000 claims description 241
- 206010028980 Neoplasm Diseases 0.000 claims description 219
- 239000003550 marker Substances 0.000 claims description 167
- 201000011510 cancer Diseases 0.000 claims description 121
- 208000020816 lung neoplasm Diseases 0.000 claims description 111
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 104
- 201000005202 lung cancer Diseases 0.000 claims description 104
- 238000004458 analytical method Methods 0.000 claims description 87
- 108090000623 proteins and genes Proteins 0.000 claims description 66
- 239000000427 antigen Substances 0.000 claims description 55
- 102000036639 antigens Human genes 0.000 claims description 55
- 108091007433 antigens Proteins 0.000 claims description 55
- 230000002380 cytological effect Effects 0.000 claims description 52
- 210000001519 tissue Anatomy 0.000 claims description 52
- 102000004169 proteins and genes Human genes 0.000 claims description 48
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 42
- 206010036790 Productive cough Diseases 0.000 claims description 41
- 208000009956 adenocarcinoma Diseases 0.000 claims description 41
- 210000003802 sputum Anatomy 0.000 claims description 41
- 208000024794 sputum Diseases 0.000 claims description 41
- 102000000905 Cadherin Human genes 0.000 claims description 30
- 108050007957 Cadherin Proteins 0.000 claims description 30
- 238000003745 diagnosis Methods 0.000 claims description 30
- 208000003849 large cell carcinoma Diseases 0.000 claims description 30
- 108050006400 Cyclin Proteins 0.000 claims description 28
- 230000027455 binding Effects 0.000 claims description 28
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims description 27
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims description 27
- 206010027406 Mesothelioma Diseases 0.000 claims description 27
- 102000001301 EGF receptor Human genes 0.000 claims description 25
- 108060006698 EGF receptor Proteins 0.000 claims description 25
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 25
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 25
- 208000000649 small cell carcinoma Diseases 0.000 claims description 24
- 230000003902 lesion Effects 0.000 claims description 23
- 230000003211 malignant effect Effects 0.000 claims description 23
- 210000004072 lung Anatomy 0.000 claims description 22
- 238000007619 statistical method Methods 0.000 claims description 22
- 102100036691 Proliferating cell nuclear antigen Human genes 0.000 claims description 21
- 102100026966 Thrombomodulin Human genes 0.000 claims description 19
- 108010079274 Thrombomodulin Proteins 0.000 claims description 19
- 108010068192 Cyclin A Proteins 0.000 claims description 15
- 230000004069 differentiation Effects 0.000 claims description 14
- 108020004414 DNA Proteins 0.000 claims description 13
- 239000000090 biomarker Substances 0.000 claims description 13
- 230000001105 regulatory effect Effects 0.000 claims description 13
- 108010017842 Telomerase Proteins 0.000 claims description 12
- 210000002919 epithelial cell Anatomy 0.000 claims description 12
- 108010008707 Mucin-1 Proteins 0.000 claims description 11
- 230000022131 cell cycle Effects 0.000 claims description 10
- -1 nm23 Proteins 0.000 claims description 10
- 108010058905 CD44v6 antigen Proteins 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 9
- 108090000790 Enzymes Proteins 0.000 claims description 9
- 230000006907 apoptotic process Effects 0.000 claims description 9
- 210000000056 organ Anatomy 0.000 claims description 9
- 230000001575 pathological effect Effects 0.000 claims description 9
- 102100021866 Hepatocyte growth factor Human genes 0.000 claims description 8
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 claims description 8
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims description 8
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 claims description 8
- 108050000637 N-cadherin Proteins 0.000 claims description 8
- 241000700605 Viruses Species 0.000 claims description 8
- 238000001574 biopsy Methods 0.000 claims description 8
- 210000001685 thyroid gland Anatomy 0.000 claims description 8
- 102000016736 Cyclin Human genes 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- 210000000481 breast Anatomy 0.000 claims description 7
- 230000002596 correlated effect Effects 0.000 claims description 7
- 239000003102 growth factor Substances 0.000 claims description 7
- 230000000877 morphologic effect Effects 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 208000035473 Communicable disease Diseases 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 6
- 102000040945 Transcription factor Human genes 0.000 claims description 6
- 108091023040 Transcription factor Proteins 0.000 claims description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 6
- 230000002068 genetic effect Effects 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 210000004185 liver Anatomy 0.000 claims description 6
- 238000000386 microscopy Methods 0.000 claims description 6
- 208000020584 Polyploidy Diseases 0.000 claims description 5
- 208000019802 Sexually transmitted disease Diseases 0.000 claims description 5
- 210000003734 kidney Anatomy 0.000 claims description 5
- 102000005962 receptors Human genes 0.000 claims description 5
- 108020003175 receptors Proteins 0.000 claims description 5
- 210000002345 respiratory system Anatomy 0.000 claims description 5
- 101100230254 Drosophila melanogaster Glut3 gene Proteins 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 102000043276 Oncogene Human genes 0.000 claims description 4
- 108700020796 Oncogene Proteins 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 101150052594 SLC2A3 gene Proteins 0.000 claims description 4
- 206010039491 Sarcoma Diseases 0.000 claims description 4
- 238000013528 artificial neural network Methods 0.000 claims description 4
- 210000001124 body fluid Anatomy 0.000 claims description 4
- 210000001185 bone marrow Anatomy 0.000 claims description 4
- 230000004663 cell proliferation Effects 0.000 claims description 4
- 230000000295 complement effect Effects 0.000 claims description 4
- 210000004907 gland Anatomy 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 210000004789 organ system Anatomy 0.000 claims description 4
- 210000000496 pancreas Anatomy 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 238000012567 pattern recognition method Methods 0.000 claims description 4
- 210000002307 prostate Anatomy 0.000 claims description 4
- 210000005000 reproductive tract Anatomy 0.000 claims description 4
- 230000003248 secreting effect Effects 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 210000001635 urinary tract Anatomy 0.000 claims description 4
- 210000002700 urine Anatomy 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- 241000233866 Fungi Species 0.000 claims description 3
- 206010018612 Gonorrhoea Diseases 0.000 claims description 3
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 102000002658 Thyroid Nuclear Factor 1 Human genes 0.000 claims description 3
- 108010057966 Thyroid Nuclear Factor 1 Proteins 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 102000044209 Tumor Suppressor Genes Human genes 0.000 claims description 3
- 108700025716 Tumor Suppressor Genes Proteins 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- 208000001786 gonorrhea Diseases 0.000 claims description 3
- 230000002458 infectious effect Effects 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 210000003205 muscle Anatomy 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 244000045947 parasite Species 0.000 claims description 3
- 230000002685 pulmonary effect Effects 0.000 claims description 3
- 208000006379 syphilis Diseases 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 241000606161 Chlamydia Species 0.000 claims description 2
- 108020005124 DNA Adducts Proteins 0.000 claims description 2
- 241000224526 Trichomonas Species 0.000 claims description 2
- 239000010839 body fluid Substances 0.000 claims description 2
- 150000003180 prostaglandins Chemical class 0.000 claims description 2
- 102000002554 Cyclin A Human genes 0.000 claims 3
- 101100065513 Homo sapiens ERAL1 gene Proteins 0.000 claims 2
- 102100034256 Mucin-1 Human genes 0.000 claims 2
- 230000005670 electromagnetic radiation Effects 0.000 claims 2
- 101150021185 FGF gene Proteins 0.000 claims 1
- 101001005719 Homo sapiens Melanoma-associated antigen 3 Proteins 0.000 claims 1
- 102100025082 Melanoma-associated antigen 3 Human genes 0.000 claims 1
- 108010007100 Pulmonary Surfactant-Associated Protein A Proteins 0.000 claims 1
- 102100027773 Pulmonary surfactant-associated protein A2 Human genes 0.000 claims 1
- 239000000975 dye Substances 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 210000002751 lymph Anatomy 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims 1
- 230000009870 specific binding Effects 0.000 claims 1
- 230000014509 gene expression Effects 0.000 abstract description 103
- 239000003147 molecular marker Substances 0.000 abstract description 17
- 238000012790 confirmation Methods 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 130
- 239000004094 surface-active agent Substances 0.000 description 48
- 108010083590 Apoproteins Proteins 0.000 description 45
- 102000006410 Apoproteins Human genes 0.000 description 45
- 230000006870 function Effects 0.000 description 45
- 238000003066 decision tree Methods 0.000 description 44
- 235000018102 proteins Nutrition 0.000 description 43
- 102000019040 Nuclear Antigens Human genes 0.000 description 38
- 108010051791 Nuclear Antigens Proteins 0.000 description 38
- 230000001028 anti-proliverative effect Effects 0.000 description 35
- 238000010186 staining Methods 0.000 description 35
- 238000013461 design Methods 0.000 description 28
- 239000011159 matrix material Substances 0.000 description 27
- 230000008569 process Effects 0.000 description 27
- 230000004083 survival effect Effects 0.000 description 24
- 230000001965 increasing effect Effects 0.000 description 23
- 238000011282 treatment Methods 0.000 description 23
- 238000011156 evaluation Methods 0.000 description 22
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 21
- 206010041067 Small cell lung cancer Diseases 0.000 description 20
- 238000005516 engineering process Methods 0.000 description 20
- 210000004940 nucleus Anatomy 0.000 description 20
- 230000002018 overexpression Effects 0.000 description 20
- 230000007170 pathology Effects 0.000 description 20
- 238000012549 training Methods 0.000 description 20
- 238000013459 approach Methods 0.000 description 19
- 238000007477 logistic regression Methods 0.000 description 19
- 208000000587 small cell lung carcinoma Diseases 0.000 description 19
- 238000004422 calculation algorithm Methods 0.000 description 18
- 239000003795 chemical substances by application Substances 0.000 description 18
- 238000004163 cytometry Methods 0.000 description 17
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 17
- 108010058546 Cyclin D1 Proteins 0.000 description 16
- 102000006311 Cyclin D1 Human genes 0.000 description 16
- 239000003580 lung surfactant Substances 0.000 description 16
- 238000012216 screening Methods 0.000 description 16
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 206010061289 metastatic neoplasm Diseases 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 14
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 14
- 238000002790 cross-validation Methods 0.000 description 14
- 238000009826 distribution Methods 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 210000000981 epithelium Anatomy 0.000 description 14
- 229940126864 fibroblast growth factor Drugs 0.000 description 14
- 229940079593 drug Drugs 0.000 description 13
- 230000004044 response Effects 0.000 description 13
- 210000004881 tumor cell Anatomy 0.000 description 13
- 102100025191 Cyclin-A2 Human genes 0.000 description 12
- 206010027476 Metastases Diseases 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- 230000008901 benefit Effects 0.000 description 12
- 210000000805 cytoplasm Anatomy 0.000 description 12
- 238000007901 in situ hybridization Methods 0.000 description 12
- 230000036210 malignancy Effects 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- 206010061309 Neoplasm progression Diseases 0.000 description 11
- 238000000540 analysis of variance Methods 0.000 description 11
- 230000002559 cytogenic effect Effects 0.000 description 11
- 238000011161 development Methods 0.000 description 11
- 230000018109 developmental process Effects 0.000 description 11
- 230000009401 metastasis Effects 0.000 description 11
- 230000005751 tumor progression Effects 0.000 description 11
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 10
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 10
- 230000003127 anti-melanomic effect Effects 0.000 description 10
- 230000008859 change Effects 0.000 description 10
- 238000002405 diagnostic procedure Methods 0.000 description 10
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 10
- 230000001976 improved effect Effects 0.000 description 10
- 230000004807 localization Effects 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 238000004393 prognosis Methods 0.000 description 10
- 108010020382 Hepatocyte Nuclear Factor 1-alpha Proteins 0.000 description 9
- 102100022057 Hepatocyte nuclear factor 1-alpha Human genes 0.000 description 9
- 102000007298 Mucin-1 Human genes 0.000 description 9
- 102100038042 Retinoblastoma-associated protein Human genes 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 238000007405 data analysis Methods 0.000 description 9
- 238000012217 deletion Methods 0.000 description 9
- 230000037430 deletion Effects 0.000 description 9
- 230000001394 metastastic effect Effects 0.000 description 9
- 238000003909 pattern recognition Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000010187 selection method Methods 0.000 description 9
- 102100037901 Pre-mRNA-splicing factor SYF2 Human genes 0.000 description 8
- 108010038795 estrogen receptors Proteins 0.000 description 8
- 102000015694 estrogen receptors Human genes 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 238000010801 machine learning Methods 0.000 description 8
- 238000012545 processing Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 102100032912 CD44 antigen Human genes 0.000 description 7
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 7
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 7
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 238000009595 pap smear Methods 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 238000013077 scoring method Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 206010008342 Cervix carcinoma Diseases 0.000 description 6
- 230000018199 S phase Effects 0.000 description 6
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 6
- 230000033115 angiogenesis Effects 0.000 description 6
- 201000010881 cervical cancer Diseases 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 230000007717 exclusion Effects 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 230000001613 neoplastic effect Effects 0.000 description 6
- 150000007523 nucleic acids Chemical group 0.000 description 6
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 5
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 5
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 description 5
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 5
- 108091052347 Glucose transporter family Proteins 0.000 description 5
- 102000013901 Nucleoside diphosphate kinase Human genes 0.000 description 5
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 5
- 101710100179 UMP-CMP kinase Proteins 0.000 description 5
- 101710119674 UMP-CMP kinase 2, mitochondrial Proteins 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 210000000038 chest Anatomy 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 238000012744 immunostaining Methods 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 229940066294 lung surfactant Drugs 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 201000001441 melanoma Diseases 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 238000012544 monitoring process Methods 0.000 description 5
- 238000011369 optimal treatment Methods 0.000 description 5
- 238000005457 optimization Methods 0.000 description 5
- 238000010837 poor prognosis Methods 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 230000002062 proliferating effect Effects 0.000 description 5
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 108091007914 CDKs Proteins 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 4
- 230000010190 G1 phase Effects 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 108700025701 Retinoblastoma Genes Proteins 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 238000013276 bronchoscopy Methods 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 238000013480 data collection Methods 0.000 description 4
- 238000013523 data management Methods 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 238000002991 immunohistochemical analysis Methods 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 210000003463 organelle Anatomy 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 230000000391 smoking effect Effects 0.000 description 4
- 102000055501 telomere Human genes 0.000 description 4
- 108091035539 telomere Proteins 0.000 description 4
- 210000003411 telomere Anatomy 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 230000006820 DNA synthesis Effects 0.000 description 3
- 101100393884 Drosophila melanogaster Glut1 gene Proteins 0.000 description 3
- 206010058314 Dysplasia Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 3
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 206010054949 Metaplasia Diseases 0.000 description 3
- 102000015728 Mucins Human genes 0.000 description 3
- 108010063954 Mucins Proteins 0.000 description 3
- 108091093105 Nuclear DNA Proteins 0.000 description 3
- 102000052575 Proto-Oncogene Human genes 0.000 description 3
- 108700020978 Proto-Oncogene Proteins 0.000 description 3
- 108050002653 Retinoblastoma protein Proteins 0.000 description 3
- 101150058068 SLC2A1 gene Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 3
- 210000002588 alveolar type II cell Anatomy 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 238000002509 fluorescent in situ hybridization Methods 0.000 description 3
- 230000004190 glucose uptake Effects 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- 238000010191 image analysis Methods 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 238000003365 immunocytochemistry Methods 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 102000006495 integrins Human genes 0.000 description 3
- 108010044426 integrins Proteins 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 238000012417 linear regression Methods 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 230000015689 metaplastic ossification Effects 0.000 description 3
- 210000001700 mitochondrial membrane Anatomy 0.000 description 3
- 239000003226 mitogen Substances 0.000 description 3
- 210000005170 neoplastic cell Anatomy 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 238000005192 partition Methods 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000012353 t test Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 230000009452 underexpressoin Effects 0.000 description 3
- 101710145634 Antigen 1 Proteins 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 description 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
- 102000007528 DNA Polymerase III Human genes 0.000 description 2
- 108010071146 DNA Polymerase III Proteins 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010027279 Facilitative Glucose Transport Proteins Proteins 0.000 description 2
- 230000035519 G0 Phase Effects 0.000 description 2
- 230000010337 G2 phase Effects 0.000 description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 2
- 102000042092 Glucose transporter family Human genes 0.000 description 2
- 206010018691 Granuloma Diseases 0.000 description 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 108010048671 Homeodomain Proteins Proteins 0.000 description 2
- 102000009331 Homeodomain Proteins Human genes 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 208000029523 Interstitial Lung disease Diseases 0.000 description 2
- 102100023974 Keratin, type II cytoskeletal 7 Human genes 0.000 description 2
- 108010070507 Keratin-7 Proteins 0.000 description 2
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 2
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 102000007296 Mucin-2 Human genes 0.000 description 2
- 108010008705 Mucin-2 Proteins 0.000 description 2
- 102000007295 Mucin-3 Human genes 0.000 description 2
- 108010008701 Mucin-3 Proteins 0.000 description 2
- 102000007270 Mucin-4 Human genes 0.000 description 2
- 108010008699 Mucin-4 Proteins 0.000 description 2
- 102000007999 Nuclear Proteins Human genes 0.000 description 2
- 108010089610 Nuclear Proteins Proteins 0.000 description 2
- 108010089430 Phosphoproteins Proteins 0.000 description 2
- 102000007982 Phosphoproteins Human genes 0.000 description 2
- 101800001156 Protein p29 Proteins 0.000 description 2
- 102000008022 Proto-Oncogene Proteins c-met Human genes 0.000 description 2
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 description 2
- 238000012952 Resampling Methods 0.000 description 2
- 201000000582 Retinoblastoma Diseases 0.000 description 2
- 108010081734 Ribonucleoproteins Proteins 0.000 description 2
- 102000004389 Ribonucleoproteins Human genes 0.000 description 2
- 108091006296 SLC2A1 Proteins 0.000 description 2
- 102100023536 Solute carrier family 2, facilitated glucose transporter member 1 Human genes 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 239000010425 asbestos Substances 0.000 description 2
- 230000003305 autocrine Effects 0.000 description 2
- 210000000270 basal cell Anatomy 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 2
- 210000005178 buccal mucosa Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 231100000357 carcinogen Toxicity 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000006369 cell cycle progression Effects 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 210000003679 cervix uteri Anatomy 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 210000003040 circulating cell Anatomy 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 230000000112 colonic effect Effects 0.000 description 2
- 238000012303 cytoplasmic staining Methods 0.000 description 2
- 238000013479 data entry Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000000762 glandular Effects 0.000 description 2
- 235000015220 hamburgers Nutrition 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000002390 hyperplastic effect Effects 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000009607 mammography Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000012737 microarray-based gene expression Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 2
- 238000013188 needle biopsy Methods 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 150000003904 phospholipids Chemical group 0.000 description 2
- 102000003998 progesterone receptors Human genes 0.000 description 2
- 108090000468 progesterone receptors Proteins 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000000611 regression analysis Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 229910052895 riebeckite Inorganic materials 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000010972 statistical evaluation Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 238000003325 tomography Methods 0.000 description 2
- 230000005758 transcription activity Effects 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 1
- 208000007879 Atypical Squamous Cells of the Cervix Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 101100493820 Caenorhabditis elegans best-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 206010008263 Cervical dysplasia Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 208000037051 Chromosomal Instability Diseases 0.000 description 1
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 241000522213 Dichilus lebeckioides Species 0.000 description 1
- 101001112318 Dictyostelium discoideum Nucleoside diphosphate kinase, cytosolic Proteins 0.000 description 1
- 101001112320 Dictyostelium discoideum Nucleoside diphosphate kinase, mitochondrial Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 1
- 241000611421 Elia Species 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 238000001159 Fisher's combined probability test Methods 0.000 description 1
- 241000287227 Fringillidae Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 108091008603 HGF receptors Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102100022623 Hepatocyte growth factor receptor Human genes 0.000 description 1
- 101710170207 High-affinity glucose transporter Proteins 0.000 description 1
- 101001128731 Homo sapiens Putative nucleoside diphosphate kinase Proteins 0.000 description 1
- 101000906283 Homo sapiens Solute carrier family 2, facilitated glucose transporter member 1 Proteins 0.000 description 1
- 101000891649 Homo sapiens Transcription elongation factor A protein-like 1 Proteins 0.000 description 1
- 241000341655 Human papillomavirus type 16 Species 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 102100023970 Keratin, type I cytoskeletal 10 Human genes 0.000 description 1
- 102100040445 Keratin, type I cytoskeletal 14 Human genes 0.000 description 1
- 102100040441 Keratin, type I cytoskeletal 16 Human genes 0.000 description 1
- 102100033511 Keratin, type I cytoskeletal 17 Human genes 0.000 description 1
- 102100033421 Keratin, type I cytoskeletal 18 Human genes 0.000 description 1
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 description 1
- 102100032700 Keratin, type I cytoskeletal 20 Human genes 0.000 description 1
- 102100025759 Keratin, type II cytoskeletal 3 Human genes 0.000 description 1
- 102100023972 Keratin, type II cytoskeletal 8 Human genes 0.000 description 1
- 108010065038 Keratin-10 Proteins 0.000 description 1
- 108010066321 Keratin-14 Proteins 0.000 description 1
- 108010066364 Keratin-16 Proteins 0.000 description 1
- 108010066325 Keratin-17 Proteins 0.000 description 1
- 108010066327 Keratin-18 Proteins 0.000 description 1
- 108010066302 Keratin-19 Proteins 0.000 description 1
- 108010066370 Keratin-20 Proteins 0.000 description 1
- 108010070918 Keratin-3 Proteins 0.000 description 1
- 108010070511 Keratin-8 Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 108010021099 Lamin Type A Proteins 0.000 description 1
- 102000008201 Lamin Type A Human genes 0.000 description 1
- 108010021101 Lamin Type B Proteins 0.000 description 1
- 206010023774 Large cell lung cancer Diseases 0.000 description 1
- 230000027311 M phase Effects 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 description 1
- 101000596402 Mus musculus Neuronal vesicle trafficking-associated protein 1 Proteins 0.000 description 1
- 101000800539 Mus musculus Translationally-controlled tumor protein Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010035916 Nuclear Matrix-Associated Proteins Proteins 0.000 description 1
- 102000008297 Nuclear Matrix-Associated Proteins Human genes 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 206010073310 Occupational exposures Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 1
- 102100022407 Probable 28S rRNA (cytosine(4447)-C(5))-methyltransferase Human genes 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 102100028588 Protein ZNRD2 Human genes 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 108010041520 Pulmonary Surfactant-Associated Proteins Proteins 0.000 description 1
- 102000000528 Pulmonary Surfactant-Associated Proteins Human genes 0.000 description 1
- 206010056342 Pulmonary mass Diseases 0.000 description 1
- 102100032116 Putative nucleoside diphosphate kinase Human genes 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 101000781972 Schizosaccharomyces pombe (strain 972 / ATCC 24843) Protein wos2 Proteins 0.000 description 1
- 208000003837 Second Primary Neoplasms Diseases 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 241000269400 Sirenidae Species 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 101001009610 Toxoplasma gondii Dense granule protein 5 Proteins 0.000 description 1
- 102100040250 Transcription elongation factor A protein-like 1 Human genes 0.000 description 1
- 108050008367 Transmembrane emp24 domain-containing protein 7 Proteins 0.000 description 1
- 206010053871 Trisomy 8 Diseases 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 102100035071 Vimentin Human genes 0.000 description 1
- 108010065472 Vimentin Proteins 0.000 description 1
- 241001537287 Viscum minimum Species 0.000 description 1
- 102100029477 Vitamin K-dependent protein C Human genes 0.000 description 1
- 101710193900 Vitamin K-dependent protein C Proteins 0.000 description 1
- 208000005248 Vocal Cord Paralysis Diseases 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 101150000319 aer gene Proteins 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 210000001552 airway epithelial cell Anatomy 0.000 description 1
- 210000001132 alveolar macrophage Anatomy 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000013103 analytical ultracentrifugation Methods 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 101150073031 cdk2 gene Proteins 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000011976 chest X-ray Methods 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000010405 clearance mechanism Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000002247 constant time method Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000005314 correlation function Methods 0.000 description 1
- 230000003583 cytomorphological effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000032459 dedifferentiation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012938 design process Methods 0.000 description 1
- 210000002451 diencephalon Anatomy 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000005669 field effect Effects 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000012100 gene-based analysis Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000006951 hyperphosphorylation Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000013394 immunophenotyping Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 201000006747 infectious mononucleosis Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000006525 intracellular process Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 238000012886 linear function Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 201000009546 lung large cell carcinoma Diseases 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000006178 malignant mesothelioma Diseases 0.000 description 1
- 101150024228 mdm2 gene Proteins 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 238000002620 method output Methods 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000020474 morphogenesis of a polarized epithelium Effects 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 229940051875 mucins Drugs 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 230000008481 normal tissue growth Effects 0.000 description 1
- 210000000299 nuclear matrix Anatomy 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 231100000675 occupational exposure Toxicity 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 238000010831 paired-sample T-test Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 210000003281 pleural cavity Anatomy 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001855 preneoplastic effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000013139 quantization Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000013102 re-test Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000012950 reanalysis Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 238000012144 step-by-step procedure Methods 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- 208000034298 trisomy chromosome 8 Diseases 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000005048 vimentin Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27463801P | 2001-03-12 | 2001-03-12 | |
| PCT/GB2002/001125 WO2002073204A2 (en) | 2001-03-12 | 2002-03-12 | Cell-based detection and differentiation of disease states |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004526154A true JP2004526154A (ja) | 2004-08-26 |
| JP2004526154A5 JP2004526154A5 (enExample) | 2005-12-22 |
Family
ID=23049031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002572414A Pending JP2004526154A (ja) | 2001-03-12 | 2002-03-12 | 細胞ベースの検出および病態の判別 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US20030199685A1 (enExample) |
| EP (1) | EP1373896A2 (enExample) |
| JP (1) | JP2004526154A (enExample) |
| KR (1) | KR20030094281A (enExample) |
| CN (1) | CN1554025A (enExample) |
| CA (1) | CA2440753A1 (enExample) |
| IL (1) | IL157872A0 (enExample) |
| NZ (1) | NZ528205A (enExample) |
| WO (1) | WO2002073204A2 (enExample) |
| ZA (1) | ZA200307121B (enExample) |
Cited By (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010526278A (ja) * | 2007-01-16 | 2010-07-29 | ムスク ファウンデーション フォー リサーチ デベロップメント | 前立腺病変の診断、治療、及び予防用組成物及び方法 |
| KR20110063753A (ko) * | 2008-09-09 | 2011-06-14 | 소마로직, 인크. | 폐암 바이오마커 및 그것들의 용도 |
| JP2012520469A (ja) * | 2009-03-12 | 2012-09-06 | キャンサー・プリヴェンション・アンド・キュア,リミテッド | 性別に基づく疾病の識別・評価・予防及び治療を含む、肺病の識別・評価・予防及び治療の方法並びにそのキット |
| JP2013521763A (ja) * | 2010-02-10 | 2013-06-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 肺癌検出用唾液バイオマーカー |
| JP2014197008A (ja) * | 2005-04-01 | 2014-10-16 | メドベット サイエンス ピーティーワイ. リミティッド | 診断法および治療法ならびにそれに有用な薬剤 |
| JP2016539345A (ja) * | 2013-09-17 | 2016-12-15 | メディカル リサーチ カウンシルMedical Research Council | 結核のバイオマーカー |
| US10422009B2 (en) | 2009-03-04 | 2019-09-24 | Genomedx Biosciences Inc. | Compositions and methods for classifying thyroid nodule disease |
| US10446272B2 (en) | 2009-12-09 | 2019-10-15 | Veracyte, Inc. | Methods and compositions for classification of samples |
| JP2020062027A (ja) * | 2008-11-17 | 2020-04-23 | ベラサイト インコーポレイテッド | 疾患診断のための分子プロファイリングの方法および組成物 |
| US10672504B2 (en) | 2008-11-17 | 2020-06-02 | Veracyte, Inc. | Algorithms for disease diagnostics |
| US10731223B2 (en) | 2009-12-09 | 2020-08-04 | Veracyte, Inc. | Algorithms for disease diagnostics |
| US10934587B2 (en) | 2009-05-07 | 2021-03-02 | Veracyte, Inc. | Methods and compositions for diagnosis of thyroid conditions |
| US11217329B1 (en) | 2017-06-23 | 2022-01-04 | Veracyte, Inc. | Methods and systems for determining biological sample integrity |
| KR20230018967A (ko) * | 2021-07-30 | 2023-02-07 | 한국 한의학 연구원 | 유사 이미지 분류를 위한 딥 러닝 성능 향상 방법 및 장치 |
| US11639527B2 (en) | 2014-11-05 | 2023-05-02 | Veracyte, Inc. | Methods for nucleic acid sequencing |
| US11769596B2 (en) | 2017-04-04 | 2023-09-26 | Lung Cancer Proteomics Llc | Plasma based protein profiling for early stage lung cancer diagnosis |
| US11976329B2 (en) | 2013-03-15 | 2024-05-07 | Veracyte, Inc. | Methods and systems for detecting usual interstitial pneumonia |
| US12297505B2 (en) | 2014-07-14 | 2025-05-13 | Veracyte, Inc. | Algorithms for disease diagnostics |
Families Citing this family (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2350692A1 (en) * | 1998-10-29 | 2000-05-11 | Cell Works Inc. | Multiple marker characterization of single cells |
| US20030190602A1 (en) * | 2001-03-12 | 2003-10-09 | Monogen, Inc. | Cell-based detection and differentiation of disease states |
| US7043500B2 (en) * | 2001-04-25 | 2006-05-09 | Board Of Regents, The University Of Texas Syxtem | Subtractive clustering for use in analysis of data |
| US7298877B1 (en) * | 2001-11-20 | 2007-11-20 | Icad, Inc. | Information fusion with Bayes networks in computer-aided detection systems |
| EP2261368A1 (en) * | 2002-03-13 | 2010-12-15 | Genomic Health, Inc. | Gene expression profiling in biopsied tumor tissues |
| US7274809B2 (en) * | 2002-08-29 | 2007-09-25 | Perceptronix Medical, Inc. And British Columbia Cancer Agency | Computerized methods and systems related to the detection of malignancy-associated changes (MAC) to detect cancer |
| EP2359689B1 (en) | 2002-09-27 | 2015-08-26 | The General Hospital Corporation | Microfluidic device for cell separation and use thereof |
| EP1422526A1 (en) * | 2002-10-28 | 2004-05-26 | MTM Laboratories AG | Method for improved diagnosis of dysplasias |
| CA2506066A1 (en) * | 2002-11-15 | 2004-06-03 | Genomic Health, Inc. | Gene expression profiling of egfr positive cancer |
| US20040122705A1 (en) * | 2002-12-18 | 2004-06-24 | Sabol John M. | Multilevel integrated medical knowledge base system and method |
| US20040122704A1 (en) * | 2002-12-18 | 2004-06-24 | Sabol John M. | Integrated medical knowledge base interface system and method |
| US20040122707A1 (en) * | 2002-12-18 | 2004-06-24 | Sabol John M. | Patient-driven medical data processing system and method |
| US20040122708A1 (en) * | 2002-12-18 | 2004-06-24 | Avinash Gopal B. | Medical data analysis method and apparatus incorporating in vitro test data |
| US20040122706A1 (en) * | 2002-12-18 | 2004-06-24 | Walker Matthew J. | Patient data acquisition system and method |
| US20040122709A1 (en) * | 2002-12-18 | 2004-06-24 | Avinash Gopal B. | Medical procedure prioritization system and method utilizing integrated knowledge base |
| US20040122702A1 (en) * | 2002-12-18 | 2004-06-24 | Sabol John M. | Medical data processing system and method |
| US20040122787A1 (en) * | 2002-12-18 | 2004-06-24 | Avinash Gopal B. | Enhanced computer-assisted medical data processing system and method |
| US7490085B2 (en) * | 2002-12-18 | 2009-02-10 | Ge Medical Systems Global Technology Company, Llc | Computer-assisted data processing system and method incorporating automated learning |
| US20040122703A1 (en) * | 2002-12-19 | 2004-06-24 | Walker Matthew J. | Medical data operating model development system and method |
| US20040231909A1 (en) | 2003-01-15 | 2004-11-25 | Tai-Yang Luh | Motorized vehicle having forward and backward differential structure |
| WO2004071572A2 (en) * | 2003-02-06 | 2004-08-26 | Genomic Health, Inc. | Gene expression markers for response to egfr inhibitor drugs |
| CA2516553C (en) * | 2003-02-20 | 2013-04-16 | Genomic Health, Inc. | Use of intronic rna to measure gene expression |
| US7668801B1 (en) * | 2003-04-21 | 2010-02-23 | At&T Corp. | Method and apparatus for optimizing queries under parametric aggregation constraints |
| EP1631689A2 (en) * | 2003-05-28 | 2006-03-08 | Genomic Health, Inc. | Gene expression markers for predicting response to chemotherapy |
| CA2527321A1 (en) * | 2003-05-30 | 2004-12-23 | Genomic Health, Inc. | Gene expression markers for response to egfr inhibitor drugs |
| WO2005039382A2 (en) * | 2003-06-24 | 2005-05-06 | Genomic Health | Prediction of likelihood of cancer recurrence |
| EP1644858B1 (en) * | 2003-07-10 | 2017-12-06 | Genomic Health, Inc. | Expression profile algorithm and test for cancer prognosis |
| US20100246837A1 (en) * | 2009-03-29 | 2010-09-30 | Krause Lee S | Systems and Methods for Tuning Automatic Speech Recognition Systems |
| AU2004284434A1 (en) * | 2003-10-16 | 2005-05-06 | Genomic Health, Inc. | qRT-PCR assay system for gene expression profiling |
| US7552035B2 (en) * | 2003-11-12 | 2009-06-23 | Siemens Corporate Research, Inc. | Method to use a receiver operator characteristics curve for model comparison in machine condition monitoring |
| WO2005047451A2 (en) * | 2003-11-12 | 2005-05-26 | Trustees Of Boston University | Isolation of nucleic acid from mouth epithelial cells |
| EP1681988B1 (en) | 2003-11-12 | 2015-04-08 | The Children's Hospital Medical Center | Method for diagnosis and treatment of pulmonary disorders |
| JP5192632B2 (ja) * | 2003-12-12 | 2013-05-08 | 愛知県 | 肺癌組織中の遺伝子発現強度を識別する方法 |
| JP4718490B2 (ja) | 2003-12-23 | 2011-07-06 | ジェノミック ヘルス, インコーポレイテッド | フラグメント化rnaの全般的増幅 |
| DE102004009934A1 (de) * | 2004-02-26 | 2005-09-22 | Niendorf, Axel, Prof.Dr.med. | Verfahren zur Untersuchung einer Gewebeprobe |
| CA2848463A1 (en) | 2004-04-09 | 2005-10-27 | Genomic Health, Inc. | Gene expression markers for predicting response to chemotherapy |
| US7991557B2 (en) * | 2004-06-19 | 2011-08-02 | Genenews Corporation | Computer system and methods for constructing biological classifiers and uses thereof |
| CA2571180A1 (en) * | 2004-06-19 | 2006-01-05 | Chondrogene, Inc. | Computer systems and methods for constructing biological classifiers and uses thereof |
| CN101115848A (zh) * | 2004-11-03 | 2008-01-30 | 阿尔马科诊断有限公司 | 转录组微阵列技术及应用该技术的方法 |
| JP4939425B2 (ja) | 2004-11-05 | 2012-05-23 | ジェノミック ヘルス, インコーポレイテッド | 乳癌の治療反応の予後および予測の分子指標 |
| CA3061785A1 (en) * | 2004-11-05 | 2006-05-18 | Genomic Health, Inc. | Predicting response to chemotherapy using gene expression markers |
| US20060136259A1 (en) * | 2004-12-17 | 2006-06-22 | General Electric Company | Multi-dimensional analysis of medical data |
| US20060136417A1 (en) * | 2004-12-17 | 2006-06-22 | General Electric Company | Method and system for search, analysis and display of structured data |
| EP1874920A4 (en) * | 2005-04-05 | 2009-11-04 | Cellpoint Diagnostics | DEVICES AND METHOD FOR ENRICHING AND CHANGING CIRCULATING TUMOR CELLS AND OTHER PARTICLES |
| US20070196820A1 (en) | 2005-04-05 | 2007-08-23 | Ravi Kapur | Devices and methods for enrichment and alteration of cells and other particles |
| EP1874962A2 (en) | 2005-04-14 | 2008-01-09 | The Trustees Of Boston University | Diagnostic for lung disorders using class prediction |
| US8351665B2 (en) * | 2005-04-28 | 2013-01-08 | The General Hospital Corporation | Systems, processes and software arrangements for evaluating information associated with an anatomical structure by an optical coherence ranging technique |
| US7766231B2 (en) * | 2005-06-24 | 2010-08-03 | Schneider Electric USA, Inc. | Devices and methods for determining the amount of individual usage of a shared commodity |
| US20070099239A1 (en) * | 2005-06-24 | 2007-05-03 | Raymond Tabibiazar | Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease |
| US8921102B2 (en) | 2005-07-29 | 2014-12-30 | Gpb Scientific, Llc | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
| JP2009508493A (ja) | 2005-09-19 | 2009-03-05 | ベリデックス・エルエルシー | すい臓がんを診断するための方法 |
| US20070078873A1 (en) * | 2005-09-30 | 2007-04-05 | Avinash Gopal B | Computer assisted domain specific entity mapping method and system |
| US9347945B2 (en) | 2005-12-22 | 2016-05-24 | Abbott Molecular Inc. | Methods and marker combinations for screening for predisposition to lung cancer |
| EP1806587A1 (en) * | 2006-01-07 | 2007-07-11 | Université de Liège | An in-vitro method for screening accessible biological markers in pathologic tissues |
| EP2605018A1 (en) * | 2006-03-09 | 2013-06-19 | The Trustees of the Boston University | Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells |
| WO2007109580A1 (en) * | 2006-03-17 | 2007-09-27 | Mayo Foundation For Medical Education And Research | Assessing lung nodules |
| US8372584B2 (en) | 2006-06-14 | 2013-02-12 | The General Hospital Corporation | Rare cell analysis using sample splitting and DNA tags |
| US20080050739A1 (en) | 2006-06-14 | 2008-02-28 | Roland Stoughton | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
| US8137912B2 (en) | 2006-06-14 | 2012-03-20 | The General Hospital Corporation | Methods for the diagnosis of fetal abnormalities |
| EP2029779A4 (en) | 2006-06-14 | 2010-01-20 | Living Microsystems Inc | HIGHLY PARALLEL SNP GENOTYPING UTILIZATION FOR FETAL DIAGNOSIS |
| US7502767B1 (en) * | 2006-07-21 | 2009-03-10 | Hewlett-Packard Development Company, L.P. | Computing a count of cases in a class |
| EP2084535B9 (en) * | 2006-09-08 | 2016-09-07 | Richard Porwancher | Bioinformatic approach to disease diagnosis |
| US7599898B2 (en) * | 2006-10-17 | 2009-10-06 | International Business Machines Corporation | Method and apparatus for improved regression modeling |
| US7892770B2 (en) * | 2007-08-24 | 2011-02-22 | Van Andel Research Institute | Monoclonal antibody which binds cMet (HGFR) in formalin-fixed and paraffin-embedded tissues and related methods |
| US8541183B2 (en) | 2007-09-11 | 2013-09-24 | Cancer Prevention And Cure, Ltd. | Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof |
| CN101990577A (zh) | 2007-09-19 | 2011-03-23 | 波士顿大学理事会 | 鉴定肺病药物开发的新途径 |
| WO2009049228A2 (en) * | 2007-10-10 | 2009-04-16 | The Regents Of The University Of Michigan | Compositions and methods for assessing disorders |
| WO2009121070A1 (en) * | 2008-03-28 | 2009-10-01 | The Trustees Of Boston University | Multifactorial methods for detecting lung disorders |
| WO2010021843A1 (en) * | 2008-08-20 | 2010-02-25 | Eli Lilly And Company | Use of antifolates in patients with detectable levels of tff-1 for the cancer treatment |
| US10359425B2 (en) | 2008-09-09 | 2019-07-23 | Somalogic, Inc. | Lung cancer biomarkers and uses thereof |
| HUE031848T2 (en) | 2008-09-20 | 2017-08-28 | Univ Leland Stanford Junior | Non-invasive diagnosis of fetal aneuploidy by sequencing |
| US20100185568A1 (en) * | 2009-01-19 | 2010-07-22 | Kibboko, Inc. | Method and System for Document Classification |
| WO2010111656A2 (en) * | 2009-03-27 | 2010-09-30 | Life Technologies Corporation | Systems and methods for assessing images |
| US20130143747A1 (en) * | 2011-12-05 | 2013-06-06 | Myriad Genetics, Incorporated | Methods of detecting cancer |
| US8811535B2 (en) * | 2009-07-17 | 2014-08-19 | Mitre Corporation | Time-frequency space constructions of families of signals |
| CA2717477A1 (en) * | 2009-09-24 | 2011-03-24 | Heidi E. Wagner | Computer based standardized method and apparatus for guiding decision support for surgical anatomic pathology operations |
| JP5931874B2 (ja) | 2010-08-13 | 2016-06-08 | ソマロジック・インコーポレーテッド | 膵癌バイオマーカーおよびその使用 |
| GB2498283A (en) * | 2010-09-08 | 2013-07-10 | Nodality Inc | Benchmarks for normal cell identification |
| US20120244141A1 (en) | 2010-09-28 | 2012-09-27 | Boehringer Ingelheim International Gmbh | Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors |
| WO2012070970A1 (ru) * | 2010-11-22 | 2012-05-31 | Farber Boris Slavinovich | Диагностический способ для прогноза развития и контроля эффективности лечения онкологических заболеваний |
| WO2012070969A1 (ru) * | 2010-11-22 | 2012-05-31 | Farber Boris Slavinovich | Диагностический способ для прогноза развития и контроля эффективности лечения сердечно-сосудистых заболеваний |
| WO2012129325A1 (en) * | 2011-03-22 | 2012-09-27 | The General Hospital Corporation | Molecular analysis of tumor samples |
| WO2013045500A1 (en) * | 2011-09-26 | 2013-04-04 | Universite Pierre Et Marie Curie (Paris 6) | Method for determining a predictive function for discriminating patients according to their disease activity status |
| CA2876405C (en) * | 2012-06-14 | 2020-01-07 | Erasmus University Medical Center Rotterdam | Methods, reagents and kits for detecting minimal residual disease |
| US10158898B2 (en) | 2012-07-26 | 2018-12-18 | Comcast Cable Communications, Llc | Customized options for consumption of content |
| US10526655B2 (en) | 2013-03-14 | 2020-01-07 | Veracyte, Inc. | Methods for evaluating COPD status |
| DK3108256T3 (da) | 2014-02-17 | 2020-09-21 | Sienna Cancer Diagnostics Ltd | Fremgangsmåde til detektering af cancer |
| JP6903672B2 (ja) * | 2016-03-08 | 2021-07-14 | マグアレイ,インコーポレイテッド | 肺癌の診断および治療のための蛋白質と自己抗体バイオマーカー |
| US10927417B2 (en) | 2016-07-08 | 2021-02-23 | Trustees Of Boston University | Gene expression-based biomarker for the detection and monitoring of bronchial premalignant lesions |
| EP4115891A1 (en) * | 2016-08-05 | 2023-01-11 | The Research Foundation for The State University of New York | Keratin 17 as a biomarker for bladder cancer |
| WO2019157214A2 (en) * | 2018-02-07 | 2019-08-15 | Ai Technologies Inc. | Deep learning-based diagnosis and referral of diseases and disorders |
| EP3935581A4 (en) | 2019-03-04 | 2022-11-30 | Iocurrents, Inc. | DATA COMPRESSION AND COMMUNICATION USING MACHINE LEARNING |
| CN110970131B (zh) * | 2019-10-24 | 2024-01-26 | 中国医科大学附属盛京医院 | 一种基于免疫球蛋白定量检测的肾小球疾病分类分型模型及其应用 |
| CN110807426B (zh) * | 2019-11-05 | 2023-11-21 | 苏州华文海智能科技有限公司 | 一种基于深度学习的寄生虫检测系统及方法 |
| CN113049344B (zh) * | 2021-04-20 | 2022-02-01 | 深圳天烁生物科技有限公司 | 细胞染色的质控品制备方法 |
| WO2023278468A1 (en) * | 2021-06-29 | 2023-01-05 | The Regents Of The University Of Michigan | Methods of determining risk of and treating cancer recurrence |
| CN116178496A (zh) * | 2022-12-08 | 2023-05-30 | 西安交通大学医学院第一附属医院 | 一种靶向识别神经内分泌肿瘤标志物insm1的短肽及其产品和应用 |
| CN119199125A (zh) * | 2024-10-31 | 2024-12-27 | 武汉大学 | 一种原位检测活循环恶性细胞中多重肺癌相关标志物及肿瘤异质化的方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4579827A (en) * | 1983-03-11 | 1986-04-01 | Sloan-Kettering Institute For Cancer Research | Monoclonal antibodies to human gastrointestinal cancers and hybridoma method of production of the monoclonal antibodies |
| WO1987006620A1 (en) | 1986-04-29 | 1987-11-05 | Murex Corporation | Diagnostic kit for sexually transmitted diseases |
| US4853770A (en) | 1988-03-01 | 1989-08-01 | Joe Schneller | Video system for viewing microscopic specimens |
| US5784162A (en) * | 1993-08-18 | 1998-07-21 | Applied Spectral Imaging Ltd. | Spectral bio-imaging methods for biological research, medical diagnostics and therapy |
| US5543291A (en) | 1993-01-29 | 1996-08-06 | Dana Farber Cancer Institute | Method of detecting carcinoma |
| SK153594A3 (en) | 1993-04-14 | 1995-07-11 | Int Murex Tech Corp | Determination method of antibodies to two or bigger number of different patogens in tested sample |
| EP0656070A4 (en) * | 1993-05-24 | 1996-03-20 | Amoco Corp | NUCLEIC ACID SAMPLES FOR LEGIONELLA GENERATIONS. |
| IT1270951B (it) * | 1993-06-07 | 1997-05-26 | Boehringer Mannheim Italia | Metodo e dispositivo per il rilevamento simultano di neisseria gonorrhoeae, chlamydia trachomatis e mycoplasma |
| EP0727664A3 (en) | 1995-02-15 | 1996-11-20 | Bayer Ag | Tumor markers to detect the recurrence of breast cancer |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| US5895748A (en) | 1996-11-27 | 1999-04-20 | Johnson; Keith R. | Panel of antibodies for detecting cadherins and catenins in tissues and method of using the panel of antibodies |
| NO308755B1 (no) * | 1996-12-20 | 2000-10-23 | Iystein Fodstad | FremgangsmÕte til karakterisering av unormale celler, anvendelse og sett for utførelse av fremgangsmÕten |
| DE69837529T2 (de) * | 1997-02-12 | 2007-07-26 | Electrophoretics Ltd., Cobham | Proteinmarker für lungenkrebs und deren verwendung |
| CN1282422A (zh) | 1997-10-21 | 2001-01-31 | 癌症研究行动技术有限公司 | 对细胞生长异常的测定 |
| US6335170B1 (en) * | 1999-02-22 | 2002-01-01 | Torben F. Orntoft | Gene expression in bladder tumors |
| AU3395900A (en) * | 1999-03-12 | 2000-10-04 | Human Genome Sciences, Inc. | Human lung cancer associated gene sequences and polypeptides |
| GB9926805D0 (en) | 1999-11-13 | 2000-01-12 | Zeneca Ltd | Diagnostic methods |
| GB0018140D0 (en) * | 2000-07-24 | 2000-09-13 | Medical Res Council | Screening for abnormalities |
| US7219016B2 (en) * | 2001-04-20 | 2007-05-15 | Yale University | Systems and methods for automated analysis of cells and tissues |
-
2002
- 2002-03-12 IL IL15787202A patent/IL157872A0/xx unknown
- 2002-03-12 EP EP02708460A patent/EP1373896A2/en not_active Withdrawn
- 2002-03-12 WO PCT/GB2002/001125 patent/WO2002073204A2/en not_active Ceased
- 2002-03-12 US US10/095,298 patent/US20030199685A1/en not_active Abandoned
- 2002-03-12 CN CNA028097599A patent/CN1554025A/zh active Pending
- 2002-03-12 NZ NZ528205A patent/NZ528205A/en unknown
- 2002-03-12 KR KR10-2003-7011975A patent/KR20030094281A/ko not_active Ceased
- 2002-03-12 US US10/095,297 patent/US6939670B2/en not_active Expired - Fee Related
- 2002-03-12 JP JP2002572414A patent/JP2004526154A/ja active Pending
- 2002-03-12 CA CA002440753A patent/CA2440753A1/en not_active Abandoned
-
2003
- 2003-09-11 ZA ZA200307121A patent/ZA200307121B/en unknown
-
2005
- 2005-05-18 US US11/131,324 patent/US20050282201A1/en not_active Abandoned
-
2007
- 2007-09-25 US US11/902,789 patent/US20080139402A1/en not_active Abandoned
Cited By (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014197008A (ja) * | 2005-04-01 | 2014-10-16 | メドベット サイエンス ピーティーワイ. リミティッド | 診断法および治療法ならびにそれに有用な薬剤 |
| JP2010526278A (ja) * | 2007-01-16 | 2010-07-29 | ムスク ファウンデーション フォー リサーチ デベロップメント | 前立腺病変の診断、治療、及び予防用組成物及び方法 |
| KR20110063753A (ko) * | 2008-09-09 | 2011-06-14 | 소마로직, 인크. | 폐암 바이오마커 및 그것들의 용도 |
| US12305238B2 (en) | 2008-11-17 | 2025-05-20 | Veracyte, Inc. | Methods for treatment of thyroid cancer |
| JP7602319B2 (ja) | 2008-11-17 | 2024-12-18 | ベラサイト インコーポレイテッド | 疾患診断のための分子プロファイリングの方法および組成物 |
| JP2020062027A (ja) * | 2008-11-17 | 2020-04-23 | ベラサイト インコーポレイテッド | 疾患診断のための分子プロファイリングの方法および組成物 |
| US10672504B2 (en) | 2008-11-17 | 2020-06-02 | Veracyte, Inc. | Algorithms for disease diagnostics |
| US10422009B2 (en) | 2009-03-04 | 2019-09-24 | Genomedx Biosciences Inc. | Compositions and methods for classifying thyroid nodule disease |
| US11474104B2 (en) | 2009-03-12 | 2022-10-18 | Cancer Prevention And Cure, Ltd. | Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof including gender-based disease identification, assessment, prevention and therapy |
| JP2012520469A (ja) * | 2009-03-12 | 2012-09-06 | キャンサー・プリヴェンション・アンド・キュア,リミテッド | 性別に基づく疾病の識別・評価・予防及び治療を含む、肺病の識別・評価・予防及び治療の方法並びにそのキット |
| US12110554B2 (en) | 2009-05-07 | 2024-10-08 | Veracyte, Inc. | Methods for classification of tissue samples as positive or negative for cancer |
| US10934587B2 (en) | 2009-05-07 | 2021-03-02 | Veracyte, Inc. | Methods and compositions for diagnosis of thyroid conditions |
| US12297503B2 (en) | 2009-05-07 | 2025-05-13 | Veracyte, Inc. | Methods for classification of tissue samples as positive or negative for cancer |
| US10731223B2 (en) | 2009-12-09 | 2020-08-04 | Veracyte, Inc. | Algorithms for disease diagnostics |
| US10446272B2 (en) | 2009-12-09 | 2019-10-15 | Veracyte, Inc. | Methods and compositions for classification of samples |
| JP2013521763A (ja) * | 2010-02-10 | 2013-06-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 肺癌検出用唾液バイオマーカー |
| US11976329B2 (en) | 2013-03-15 | 2024-05-07 | Veracyte, Inc. | Methods and systems for detecting usual interstitial pneumonia |
| JP2016539345A (ja) * | 2013-09-17 | 2016-12-15 | メディカル リサーチ カウンシルMedical Research Council | 結核のバイオマーカー |
| US12297505B2 (en) | 2014-07-14 | 2025-05-13 | Veracyte, Inc. | Algorithms for disease diagnostics |
| US11639527B2 (en) | 2014-11-05 | 2023-05-02 | Veracyte, Inc. | Methods for nucleic acid sequencing |
| US11769596B2 (en) | 2017-04-04 | 2023-09-26 | Lung Cancer Proteomics Llc | Plasma based protein profiling for early stage lung cancer diagnosis |
| US11217329B1 (en) | 2017-06-23 | 2022-01-04 | Veracyte, Inc. | Methods and systems for determining biological sample integrity |
| KR20230018967A (ko) * | 2021-07-30 | 2023-02-07 | 한국 한의학 연구원 | 유사 이미지 분류를 위한 딥 러닝 성능 향상 방법 및 장치 |
| KR102830294B1 (ko) | 2021-07-30 | 2025-07-08 | 한국 한의학 연구원 | 유사 이미지 분류를 위한 딥 러닝 성능 향상 방법 및 장치 |
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200307121B (en) | 2004-12-13 |
| NZ528205A (en) | 2006-09-29 |
| CA2440753A1 (en) | 2002-09-19 |
| US6939670B2 (en) | 2005-09-06 |
| US20080139402A1 (en) | 2008-06-12 |
| US20030199685A1 (en) | 2003-10-23 |
| US20050282201A1 (en) | 2005-12-22 |
| US20030104499A1 (en) | 2003-06-05 |
| EP1373896A2 (en) | 2004-01-02 |
| CN1554025A (zh) | 2004-12-08 |
| WO2002073204A3 (en) | 2003-10-30 |
| IL157872A0 (en) | 2004-03-28 |
| WO2002073204A2 (en) | 2002-09-19 |
| KR20030094281A (ko) | 2003-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004526154A (ja) | 細胞ベースの検出および病態の判別 | |
| ZA200502575B (en) | Cell-based detection and differentiation of disease states | |
| Park et al. | Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma | |
| JP5184087B2 (ja) | ガンの予後のためのマーカー候補を分析および最適化するための方法およびコンピュータープログラム製品 | |
| Sigel et al. | Predicting pulmonary adenocarcinoma outcome based on a cytology grading system | |
| Connolly et al. | Role of the Surgical Pathologist in the Diagnosis and Management of the Cancer Patient | |
| Kuang et al. | FGB and FGG derived from plasma exosomes as potential biomarkers to distinguish benign from malignant pulmonary nodules | |
| CN105319364A (zh) | 用于预测小肝癌复发的联合诊断标记 | |
| Xue et al. | Deep learning to automatically evaluate HER2 gene amplification status from fluorescence in situ hybridization images | |
| Nicholson et al. | An update on the status of molecular testing for the indeterminate thyroid nodule and risk stratification of differentiated thyroid cancer | |
| Graham et al. | Hepatic adenomas with synchronous or metachronous fibrolamellar carcinomas: both are characterized by LFABP loss | |
| Shishido et al. | Cancer-related cells and oncosomes in the liquid biopsy of pancreatic cancer patients undergoing surgery | |
| Oh et al. | Multiplexed single‐cell analysis of FNA allows accurate diagnosis of salivary gland tumors | |
| Tian et al. | Prediction of HER2 status via random forest in 3257 Chinese patients with gastric cancer | |
| Meng et al. | Mutant-specific BRAF and CD117 immunocytochemistry potentially facilitate risk stratification for papillary thyroid carcinoma in fine-needle aspiration biopsy specimens | |
| Konchuba et al. | Deoxyribonucleic acid cytometric analysis of prostate core biopsy specimens: relationship to serum prostate specific antigen and prostatic acid phosphatase, clinical stage and histopathology | |
| Gonzalez-Farre et al. | Automated quantification of stromal tumour infiltrating lymphocytes is associated with prognosis in breast cancer | |
| Gülmez et al. | The role of CD133 expression of cancer stem cells on radiotherapy response in early stage glottic cancers | |
| Punjabi et al. | Three shades of an unusual mediastinal tumour | |
| Jansen et al. | Protein profiling in pathology: analysis and evaluation of 239 frozen tissue biopsies for diagnosis of B‐cell lymphomas | |
| CN121049516A (zh) | 一种用于肺鳞癌诊断的联合诊断标志物的应用 | |
| AU2002242823A1 (en) | Cell-based detection and differentiation of disease states | |
| Companion | 4 min read Accelerating Diagnosis with Digital Pathology Based Biomarker Analysis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050202 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050202 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080229 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080725 |